Antifungal agents: an overview. Part II

J Am Acad Dermatol. 1994 Jun;30(6):911-33; quiz 934-6. doi: 10.1016/s0190-9622(94)70112-1.

Abstract

The recent introduction of a new generation of antifungal drugs promises to alter significantly therapy for both systemic and superficial mycoses, in particular, onychomycosis. This article presents an in-depth review of the azoles (the triazoles itraconazole and fluconazole), the allylamines (naftifine and terbinafine), and the morpholine derivative amorolfine.

Publication types

  • Review

MeSH terms

  • Allylamine / analogs & derivatives
  • Allylamine / metabolism
  • Allylamine / pharmacokinetics
  • Allylamine / therapeutic use
  • Antifungal Agents / metabolism
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / therapeutic use*
  • Azoles / metabolism
  • Azoles / pharmacokinetics
  • Azoles / therapeutic use
  • Dermatomycoses / drug therapy
  • Humans
  • Morpholines / metabolism
  • Morpholines / pharmacokinetics
  • Morpholines / therapeutic use
  • Naphthalenes / metabolism
  • Naphthalenes / pharmacokinetics
  • Naphthalenes / therapeutic use
  • Onychomycosis / drug therapy
  • Terbinafine

Substances

  • Antifungal Agents
  • Azoles
  • Morpholines
  • Naphthalenes
  • Allylamine
  • naftifine
  • amorolfine
  • Terbinafine